期刊文献+

冠通方对冠状动脉裸金属支架植入术后再狭窄的影响 被引量:10

Effect of Guantong Formula on the Restenosis after Intracoronary Bare Stenting
原文传递
导出
摘要 目的观察冠通方对冠状动脉内裸金属支架植入术后再狭窄的影响。方法120例冠心病冠状动脉裸金属支架植入患者随机分为对照组和治疗组各60例,对照组常规用药,治疗组在此基础上服用冠通方,两组均治疗6个月。冠状动脉定量分析术前、术后即刻和治疗结束后冠状动脉造影图像,比较治疗后两组再狭窄率及支架植入血管段内径情况。结果对照组再狭窄率为23.73%,治疗组为9.84%,两组再狭窄率比较差异有统计学意义(P<0.05)。治疗后治疗组晚期内径丢失小于对照组(P<0.05),支架植入血管段最小内径、管腔内径净获得、管腔面积净获得均大于对照组(P<0.05或P<0.01)。结论冠通方可减少冠状动脉裸金属支架植入术后再狭窄的发生率。 Objective To evaluate the effect of Guantong Formula(Formula for the stenosis of coronary artery)on the restenosis after intracoronary bare stenting.Methods Totally 120 patients after successful intracoronary bare stenting were randomized into control group and treatment group.The control group was treated with routine medicines,based on which the treatment group was administered Guantong Formula.The treatment course was 6 months.Quantitative coronary analysis was made for all patients with the angiograms of pre-intervention,post-intervention and follow-up for comparing the incidence of restenosis and diameter of involved blood vessel of both groups.Results The coronary angiographic examination showed that the restenosis rate of the control group was 23.73% while that of the treatment group was 9.84%,the difference was significant(P0.05).After treatment,in the late stage,the loss of diameter in the treatment group was smaller than that of the control group(P0.05),the minimum diameter,the net gain of luminal diameter,and the net gain of luminal area were all larger than those of the control group(P0.05 or P0.01).Conclusion Guantong Formula is effective in preventing restenosis after intracoronary bare stenting.
出处 《中医杂志》 CSCD 北大核心 2010年第5期423-425,共3页 Journal of Traditional Chinese Medicine
基金 广西科学研究与技术开发计划(桂科攻0592007-3)
关键词 冠通方 冠状动脉支架植入术 冠状动脉再狭窄 Guantong Formula(Formula for the stenosis of coronary artery) Intracoronary stenting Restenosis of the coronary artery
  • 相关文献

参考文献12

二级参考文献52

  • 1吴永健,宋光远,杨跃进.冠心病介入治疗中的药物支架(一)[J].中国医疗器械信息,2005,11(2):45-46. 被引量:10
  • 2CHEN Ke-ji,SHI Da-zhuo,XU Hao,LUE Shu-zheng,LI Tian-chang,KE Yuan-nan,ZHANG Min-zhou,LU Xiao-yan,SUN Rui-yuan,YOU Shi-jie.XS0601 REDUCES THE INCIDENCE OF RESTENOSIS: A PROSPECTIVE STUDY OF 335 PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION IN CHINA[J].Chinese Medical Journal,2006(1):6-13. 被引量:87
  • 3鹿小燕,史大卓,徐浩,陈可冀,吕树铮.芎芍胶囊干预冠心病介入治疗后再狭窄的研究[J].中国中西医结合杂志,2006,26(1):13-17. 被引量:65
  • 4中国中西医结合研究会活血化瘀专业委员会.血瘀证诊断标准[J].中西医结合杂志,1987,(3):129-129.
  • 5王阶.血瘀证诊断标准的研究[A].见:陈可冀主编.活血化瘀研究与临床[C].北京:北京医科大学中国协和医科大学联合出版社,1993.7.
  • 6中国中西医结合学会心血管病学会.冠心病中医诊断标准.中西医结合杂志,1991,11(5):257-257.
  • 7Faxon DP,Coats W, Currier J. Remodeling of the coronary artery after vaseular[J]. Prog Cardiovasc Dis, 1997,40:129 -140.
  • 8Kitazume H, Kubo I, I wama T, et al. Long - term angiographic follow - up of lesion patent 6 months after percutaneous coronary angioplasty[J]. Am Heart L, 1995,129: 441 - 444.
  • 9Landzberg BR, Frishman WH, Lerrick K. Pathophysiology and pharmacologicala approaches for prevrntion of coronary artery restenosis following coronary balloon angioplasty and related procedures [J]. Progress Cardiovascular Disease, 1997,9 : 361.
  • 10Myllam M, Frosen J, Calderon T, et al. Selective tyrosine kinase inhibitor for the PDGF - R in vitro inhibits SMC Proliferation after vein injury of arterial intinal invivo[J]. Cardiovase Drug Therp, 1999,13 (2) : 159.

共引文献452

同被引文献173

引证文献10

二级引证文献33

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部